Rezdiffra Uptake Held Up By Payers, But Not Biopsy Requirements

Initial prescriptions for Madrigal Pharmaceuticals, Inc.’s Rezdiffra (resmetirom) are running into payer-related delays, but not because payers want biopsy-based disease confirmation, according to key opinion leaders discussing the metabolic dysfunction-associated steatohepatitis (MASH) and obesity treatment landscapes at a recent Leerink Partners event. Meanwhile, a note issued by Leerink on 14 July cited KOLs saying Eli Lilly and Company’s Zepbound (tirzepatide) offers the best overall clinical profile in obesity therapy.

During an inflammation and immunology therapeutics forum convened by Leerink on 9 July, the firm’s analysts interviewed a pair of...